Thymosin-alpha 1 cut deaths 3% to 5.8%, on 460 people
A hepatitis B injection showed fewer deaths and complications in 1,349 patients — but the trials were too small to be sure.
By The Weekend · · 4 min read
In three trials covering 907 adults with chronic hepatitis B, 14 of 460 people given thymosin-alpha 1 died, compared with 26 of 447 on standard care or placebo — a drop from 5.8% to 3% within two years. That is the whole case for a drug that has circulated in liver clinics for over a decade without settling what it does for the disease itself.
A person with hepatitis B hears "fewer deaths." A doctor hears "wide confidence interval."
For someone living with chronic hepatitis B — a virus that can quietly scar the liver for decades before announcing itself as cirrhosis or cancer — a treatment that lowers the death rate by nearly half sounds like the headline that matters. And on the numbers as reported, it is real: the death reduction held across the pooled trials, as did a fall in serious unwanted effects, from 13.4% to 10.1% in five studies covering 1,056 people. Non-serious side effects also dropped, from 21.5% to 10.6% in a smaller pool of 300 people.
What thymosin-alpha 1 did not move, on the same evidence, was hepatitis B-related illness itself — 8.8% versus 7.6%, a gap too small to call a difference — nor liver health, nor how people said they felt five years out, in the one study that asked. That is an unusual split: the drug that may keep you alive without demonstrably changing the disease that's threatening you. It's not a contradiction so much as a sign that the trials weren't built to catch improvement in liver scarring or viral suppression the way they were built to count deaths.
A thymus-gland extract has been chasing a licence since the 1990s
Thymosin-alpha 1 is a peptide produced by the thymus, the gland behind the breastbone that trains immune cells early in life. Isolated and synthesized decades ago, it was proposed as a way to nudge a weakened immune response into recognizing and clearing the hepatitis B virus, given as a subcutaneous injection rather than a pill. It reached markets in parts of Asia, the Middle East and Latin America under the brand name Zadaxin, but never secured approval in the United States or the European Union, where interferon and then oral antivirals like lamivudine, entecavir and tenofovir became the standard treatments instead.
That gap in approval is why this evidence review matters more than it might for an established drug: thymosin-alpha 1 has spent 30 years as a treatment used in some countries, trialed in others, and settled nowhere. The ten trials pooled here — 1,349 people in total, funded by a mix of universities, pharmaceutical companies, national health bodies and research grants — ranged from 12 participants to 690, tested the drug alone and alongside the antivirals that already work, and were run against placebo in two studies, no treatment in two more, and matched background therapy in the remaining six. That variation in comparator is itself a signal: nobody has run one large, uniform trial answering one clean question.
The catch is in the label "may"
Every meaningful result in this review is qualified as low-certainty evidence — not because the numbers are fabricated or the trials dishonest, but because small trial sizes, inconsistent designs and gaps in blinding mean the true effect could sit well above or below what was measured. A death rate that fell from 5.8% to 3% across 907 people is a suggestive signal, not a settled fact; with more participants, that gap could narrow to nothing or widen further. The reviewers are explicit that future trials need to be larger and more rigorously designed before anyone should treat the death and complication findings as reliable rather than promising.
There's also no funder-neutral trial in the mix large enough to anchor the finding. Pharmaceutical-industry funding sat alongside university and national grants across the ten studies, which isn't disqualifying — plenty of good drug trials are industry-funded — but it means no single well-resourced, independently run trial exists to confirm or contradict the pooled signal. For a drug already sold commercially in several countries, that's the quiet cost of never having gone through the kind of large regulatory trial that tenofovir and entecavir did on their way to becoming first-line treatment.
What nobody has tested is whether it beats the drugs already working
The open question isn't whether thymosin-alpha 1 does anything — the mortality and complication numbers suggest it might — it's whether adding it to tenofovir or entecavir, the antivirals that already suppress hepatitis B effectively in most patients, produces a benefit large enough to justify the injections, the cost and the uncertainty, over those drugs alone. None of the ten trials were large enough or long enough to answer that comparison with confidence, and until one is, thymosin-alpha 1 remains a treatment some countries have licensed and clinics have used, resting on evidence that reviewers themselves rate as too thin to call definitive.
Is thymosin-alpha 1 approved in the United States?
No — it has not received FDA approval and is not part of standard US hepatitis B treatment guidelines.
Does thymosin-alpha 1 replace antiviral drugs like tenofovir?
No trial in this review tested it as a replacement; it was studied alongside or against standard antivirals, not instead of them.